Midkine: A promising molecule for drug development to treat diseases of the central nervous system

Current Pharmaceutical Design

Volumn 17, Issue 5, 2011, Pages 410-423

  Muramatsu, Takashi ^a  

^a AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Cerebral infarction; Drug discovery; Glioblastoma; Ischemia; Midkine; Multiple sclerosis; Neurodegenerative diseases

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTISENSE OLIGODEOXYNUCLEOTIDE; APTAMER; CHONDROITIN 6 SULFATE; COMPLEMENTARY DNA; CYTOKINE RECEPTOR ANTAGONIST; MIDKINE; SMALL INTERFERING RNA;

ARTICLE; BRAIN INFARCTION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MATURATION; CELL REGENERATION; CENTRAL NERVOUS SYSTEM DISEASE; DEGENERATIVE DISEASE; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; INFLAMMATION; MULTIPLE SCLEROSIS; NEOINTIMA; NEOPLASM; NEPHRITIS; NERVE CELL NECROSIS; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; XENOPUS;

AMINO ACID SEQUENCE; ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; CYTOKINES; DRUG DISCOVERY; HUMANS; INFLAMMATION; NEOPLASMS; NEUROGENESIS;

EID: 79953325739     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161211795164167     Document Type: Article

References (203)

1. Muramatsu T. Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem 2002; 132: 359-71.
2. Kadomatsu K, Muramatsu T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett 204: 127-43.
3. Muramatsu T. Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases. Proc Jpn Acad Ser B Phys Biol Sci 2010; 86: 410-25.
4. Tomomura M, Kadomatsu K, Matsubara S, Muramatsu T. A retinoic acid-responsive gene, MK, found in the teratocarcinoma system. Heterogeneity of the transcript and the nature of the translation product. J Biol Chem 1990;265:10765-70.
5. Merenmies J, Rauvala H. Molecular cloning of the 18-kDa growth associated protein of developing brain. J Biol Chem 1990; 265: 16721-4.
6. Li YS, Milner PG, Chauhan AK, et al. Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity. Science 1990; 250: 1690-4.
7. Rauvala H, Peng HB. HB-GAM (heparin-binding growth associated molecule) and heparin-type glycans in the development and plasticity of neuron-target contacts. Prog Neurobiol 1997; 52: 127-44.
8. Deuel TF, Zhang N, Yeh HJ, Silos-Santiago I, Wang ZY. Pleiotrophin: a cytokine with diverse functions and a novel signaling pathway. Arch Biochem Biophys 2002; 397: 162-71.
9. Kadomatsu K, Huang RP, Suganuma T, Murata F, Muramatsu T. A retinoic acid responsive gene MK found in the teratocarcinoma sys- tem is expressed in spatially and temporally controlled manner during mouse embryogenesis. J Cell Biol 1990; 110: 607-16.
10. Tsutsui J, Kadomatsu K, Matsubara S, et al. A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms' tumor and other human carcinomas. Cancer Res 1993; 53: 1281-5.
11. Yoshida Y, Goto M, Tsutsui J, et al. Midkine is present in the early stage of cerebral infarct. Brain Res Dev Brain Res 1995; 85: 25-30.
12. Muramatsu T. Midkine (MK), the product of a retinoic acid responsive gene, and pleiotrophin constitute a new protein family regulating growth and differentiation. Int J Dev Biol 1993; 37: 183-8.
13. Kadomatsu K, Tomomura M, Muramatsu T. cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis. Biochem Biophys Res Commun 1988; 151: 1312-8.
14. Rauvala H. An 18-kd heparin-binding protein of developing brain that is distinct from fibroblast growth factors. EMBO J 1989; 8: 2933-41.
15. Milner PG, Li YS, Hoffman RM, Kodner CM, Siegel NR, Deuel TF. A novel 17 kD heparin-binding growth factor (HBGF-8) in bovine uterus: purification and N-terminal amino acid sequence. Biochem Biophys Res Commun. 1989; 165: 1096-103.
16. Vigny M, Raulais D, Puzenat N, et al. Identification of a new heparin-binding protein localized within chick basement membranes. Eur J Biochem 1989; 186: 733-40.
17. Urios P, Duprez D, Le Caer JP, Courtois Y, Vigny M, Laurent M. Molecular cloning of RI-HB, a heparin binding protein regulated by retinoic acid. Biochem Biophys Res Commun. 1991; 175: 61724.
18. Tsutsui J, Uehara K, Kadomatsu K, Matsubara S, Muramatsu T. A new family of heparin-binding factors: strong conservation of midkine (MK) sequences between the human and the mouse. Biochem Biophys Res Commun 1991; 176: 792-7.
19. Kretschmer PJ, Fairhurst JL, Decker MM, et al. Cloning, characterization and developmental regulation of two members of a novel human gene family of neurite outgrowth-promoting proteins. Growth Factors 1991; 5: 99-114.
20. Fu C, Maminta-Smith LD, Guo C, Deuel TF. Cloning and sequence of the Xenopus laevis homologue of the midkine cDNA. Gene 1994; 146: 311-2.
21. Winkler C, Schafer M, Duschl J, Schartl M, Volff JN. Functional divergence of two zebrafish midkine growth factors following fishspecific gene duplication. Genome Res 2003; 13: 1067-81.
22. Englund C, Birve A, Falileeva L, Grabbe C, Palmer RH. Miple1 and miple2 encode a family of MK/PTN homologues in Drosophila melanogaster. Dev Genes Evol 2006; 216: 10-8.
23. Kilpelainen I, Kaksonen M, Kinnunen T, et al. Heparin-binding growth-associated molecule contains two heparin-binding β-sheet domains that are homologous to the thrombospondin type I repeat. J Biol Chem 2000; 275: 13564-70.
24. Fabri L, Maruta H, Muramatsu H, et al. Structural characterization of native and recombinant forms of the neurotrophic cytokine MK. J Chromatogr 1993; 646: 213-25.
25. Iwasaki W, Nagata K, Hatanaka H, et al. Solution structure of midkine, a new heparin-binding growth factor. EMBO J 1997; 16: 6936-46.
26. Akhter S, Ichihara-Tanaka K, Kojima S, et al. Clusters of basic amino acids in midkine: roles in neurite-promoting activity and plasminogen activator-enhancing activity. J Biochem 1998; 123: 1127-36.
27. Muramatsu H, Inui T, Kimura T, et al. Localization of heparinbinding, neurite outgrowth and antigenic regions in the midkine molecule. Biochem Biophys Res Commun 1994; 203: 1131-9.
28. Diamantopoulou Z, Bermek O, Polykratis A, et al. A Pleiotrophin C-terminus peptide induces anti-cancer effects through RPTP /. Mol Cancer 2010; 9: 224.
29. Asai T, Watanabe K, Ichihara-Tanaka K, et al. Identification of heparin-binding sites in midkine and their role in neuritepromotion. Biochem Biophys Res Commun 1997; 236: 66-70.
30. Maeda N, Ichihara-Tanaka K, Kimura T, Kadomatsu K, Muramatsu T, Noda M. A receptor-like protein-tyrosine phosphatase TPζ/RPTPβ binds a heparin-binding growth factor midkine. In-volvement of arginine 78 of midkine in the high affinity binding to PTP. J Biol Chem 1999; 274: 12474-9.
31. Kojima S, Inui T, Muramatsu H, et al. Dimerization of midkine by tissue transglutaminase and its functional implication. J Biol Chem 1997; 272: 9410-6.
32. Kaname T, Kuwano A, Murano I, Uehara K, Muramatsu T, Kajii T. Midkine gene (MDK), a gene for prenatal differentiation and neuroregulation, maps to band 11p11.2 by fluorescence in situ hybridization. Genomics 1993; 17: 514-5.
33. Simon-Chazottes D, Matsubara S, Miyauchi T, Muramatsu T, Guenet JL. Chromosomal localization of two cell surfaceassociated molecules of potential importance in development: midkine (Mdk) and basigin (Bsg). Mamm Genome 1992; 2: 269-71.
34. http://www.ncbi.nlm.nih.gov/gene
35. Li YS, Hoffman RM, Le Beau MM, et al. Characterization of the human pleiotrophin gene. Promoter region and chromosomal localization. J Biol Chem 1992; 267: 26011-6.
36. Matsubara S, Tomomura M, Kadomatsu K, Muramatsu T. Structure of a retinoic acid-responsive gene, MK, which is transiently activated during the differentiation of embryonal carcinoma cells and the mid-gestation period of mouse embryogenesis. J Biol Chem 1990; 265: 9441-3.
37. Uehara K, Matsubara S, Kadomatsu K, Tsutsui J, Muramatsu T. Genomic structure of human midkine (MK), a retinoic acidresponsive growth/differentiation factor. J Biochem 1992; 111: 563-7.
38. Lai S, Czubayko F, Riegel AT, Wellstein A. Structure of the human heparin-binding growth factor gene pleiotrophin. Biochem Biophys Res Commun 1992; 187: 1113-22.
39. Kaname T, Kadomatsu K, Aridome K, et al. The expression of truncated MK in human tumors. Biochem Biophys Res Commun 1996; 219: 256-60.
40. Matsubara S, Take M, Pedraza C, Muramatsu T. Mapping and characterization of a retinoic acid-responsive enhancer of midkine, a novel heparin-binding growth/differentiation factor with neurotrophic activity. J Biochem.1994; 115: 1088-96.
41. Pedraza C, Matsubara S, Muramatsu T. A retinoic acid-responsive element in human midkine gene. J Biochem. 1995; 117: 845-9.
42. Kaplan F, Comber J, Sladek R, et al. The growth factor midkine is modulated by both glucocorticoid and retinoid in fetal lung development. Am J Respir Cell Mol Biol. 2003; 28: 33-41.
43. Adachi Y, Matsubara S, Pedraza C, et al. Midkine as a novel target gene for the Wilms' tumor suppressor gene (WT1). Oncogene 1996; 13: 2197-203.
44. Reynolds PR, Mucenski ML, Le Cras TD, Nichols WC, Whitsett JA. Midkine is regulated by hypoxia and causes pulmonary vascular remodeling. J Biol Chem 2004; 279: 37124-32.
45. Hobo A, Yuzawa Y, Kosugi T, et al. The growth factor midkine regulates the renin-angiotensin system in mice. J Clin Invest 2009; 119: 1616-25.
46. Muramatsu H, Muramatsu T. Purification of recombinant midkine and examination of its biological activities: functional comparison of new heparin binding factors. Biochem Biophys Res Commun 1991; 177: 652-8.
47. Muramatsu H, Shirahama H, Yonezawa S, Maruta H, Muramatsu T. Midkine, a retinoic acid-inducible growth/differentiation factor: immunochemical evidence for the function and distribution. Dev Biol 1993; 159: 392-402.
48. Takei Y, Kadomatsu K, Matsuo S, et al. Antisense oligodeoxynucleotide targeted to midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res 2001; 61: 8486-91.
49. Michikawa M, Kikuchi S, Muramatsu H, Muramatsu T, Kim SU. Retinoic acid responsive gene product, midkine, has neurotrophic functions for mouse spinal cord and dorsal root ganglion neurons in culture. J Neurosci Res 1993; 35: 530-9.
50. Kikuchi S, Muramatsu H, Muramatsu T, Kim SU. Midkine, a novel neurotrophic factor, promotes survival of mesencephalic neurons in culture. Neurosci Lett 1993; 160: 9-12.
51. Satoh J, Muramatsu H, Moretto G, et al. Midkine that promotes survival of fetal human neurons is produced by fetal human astrocytes in culture. Brain Res Dev Brain Res 1993; 75: 201-5.
52. Owada K, Sanjo N, Kobayashi T, et al. Midkine inhibits caspasedependent apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase in cultured neurons. J Neurochem 1999; 73: 2084-92.
53. Takada T, Toriyama K, Muramatsu H, Song XJ, Torii S, Muramatsu T. Midkine, a retinoic acid-inducible heparin-binding cytokine in inflammatory responses: chemotactic activity to neutrophils and association with inflammatory synovitis. J Biochem 1997; 122: 453-8.
54. Horiba M, Kadomatsu K, Nakamura E, et al. Neointima formation in a restenosis model is suppressed in midkine-deficient mice. J Clin Invest. 2000; 105: 489-95.
55. Qi M, Ikematsu S, Maeda N, et al. Haptotactic migration induced by midkine. Involvement of protein-tyrosine phosphatase ζ. Mitogen-activated protein kinase, and phosphatidylinositol 3-kinase. J Biol Chem 2001; 276: 15868-75.
56. Kaneda N, Talukder AH, Nishiyama H, Koizumi S, Muramatsu T. Midkine, a heparin-binding growth/differentiation factor, exhibits nerve cell adhesion and guidance activity for neurite outgrowth in vitro. J Biochem 1996; 119: 1150-6.
57. Kojima S, Muramatsu H, Amanuma H, Muramatsu T. Midkine enhances fibrinolytic activity of bovine endothelial cells. J Biol Chem 1995; 270: 9590-6.
58. Yamada H, Inazumi T, Tajima S, Muramatsu H, Muramatsu T. Stimulation of collagen expression and glycosaminoglycan synthesis by midkine in human skin fibroblasts. Arch Dermatol Res 1997; 289: 429-33.
59. Sato W, Kadomatsu K, Yuzawa Y, et al. Midkine is involved in neutrophil infiltration into the tubulointerstitium in ischemic renal injury. J Immunol 2001; 167: 3463-9.
60. Sumi Y, Muramatsu H, Takei Y, Hata K, Ueda M, Muramatsu T. Midkine, a heparin-binding growth factor, promotes growth and glycosaminoglycan synthesis of endothelial cells through its action on smooth muscle cells in an artificial blood vessel model. J Cell Sci 2002; 115: 2659-67.
61. Tomomura M, Kadomatsu K, Nakamoto M, et al. A retinoic acid responsive gene, MK, produces a secreted protein with heparin binding activity. Biochem Biophys Res Commun 1990; 171: 603-9.
62. Hayashi K, Kadomatsu K, Muramatsu T. Requirement of chondroitin sulfate/dermatan sulfate recognition in midkine-dependent migration of macrophages. Glycoconj J 2001; 18: 401-6.
63. Kaneda N, Talukder AH, Ishihara M, Hara S, Yoshida K, Muramatsu T. Structural characteristics of heparin-line domain required for interaction of midkine with embryonic neurons. Biochem Biophys Res Commun 1996; 220: 108-12.
64. Ueoka C, Kaneda N, Okazaki I, Nadanaka S, Muramatsu T, Sugahara K. Neuronal cell adhesion, mediated by the heparinbinding neuroregulatory factor midkine, is specifically inhibited by chondroitin sulfate E. Structural ans functional implications of the over-sulfated chondroitin sulfate. J Biol Chem 2000; 275: 3740713.
65. Zou P, Zou K, Muramatsu H, et al. Glycosaminoglycan structures required for strong binding to midkine, a heparin-binding growth factor. Glycobiology 2003; 13: 35-42.
66. Muramatsu T, Muramatsu H, Kaneda N, Sugahara K. Recognition of glycosaminoglycans by midkine. Methods Enzymol 2003; 363: 365-76.
67. Sakaguchi N, Muramatsu H, Ichihara-Tanaka K, et al. Receptortype protein tyrosine phosphatase ζ as a component of the signaling receptor complex for midkine-dependent survival of embryonic neurons. Neurosci Res 2003; 45: 219-24.
68. Margolis RK, Rauch U, Maurel P, Margolis RU. Neurocan and phosphacan: two major nervous tissue-specific chondroitin sulfate proteoglycans. Perspect Dev Neurobiol 1996; 3: 273-90.
69. Maeda N, Nishiwaki T, Shintani T, Hamanaka H, Noda M. 6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase /RPTP, binds pleiotrophin/heparinbinding growth-associated molecule (HB-GAM). J Biol Chem 1996; 271: 21446-52.
70. Mitsiadis TA, Salmivirta M, Muramatsu T, et al. Expression of the heparin-binding cytokines, midkine (MK) and HB-GAM (pleiotrophin) is associated with epithelial-mesenchymal interactions during fetal development and organogenesis. Development 1995; 121: 3751.
71. Kojima T, Katsumi A, Yamazaki T, et al. Human ryudocan from endothelium-like cells binds basic fibroblast growth factor, midkine, and tissue factor pathway inhibitor. J Biol Chem 1996; 271: 5914-20.
72. Nakanishi T, Kadomatsu K, Okamoto T, et al. Expression of syndecan-1 and -3 during embryogenesis of the central nervous system in relation to binding with midkine. J Biochem 1997; 121: 197-205.
73. Kurosawa N, Chen GY, Kadomatsu K, Ikematsu S, Sakuma S, Muramatsu T. Glypican-2 binds to midkine: the role of glypican-2 in neuronal cell adhesion and neurite outgrowth. Glycoconj J.2001; 18: 499-507.
74. Zou K, Muramatsu H, Ikematsu S, et al. A heparin-binding growth factor, midkine, binds to a chondroitin sulfate proteoglycan, PGM/versican. Eur J Biochem 2000; 267: 4046-53.
75. Ichihara-Tanaka K, Oohira A, Rumsby M, Muramatsu T. Neuroglycan C is a novel midkine receptor involved in process elongation of oligodendroglial precursor-like cells. J Biol Chem 2006; 281: 30857-64.
76. Muramatsu H, Zou K, Sakaguchi N, Ikematsu S, Sakuma S, Muramatsu T. LDL receptor-related protein as a component of the midkine receptor. Biochem Biophys Res Commun 2000; 270: 93641.
77. Muramatsu H, Zou P, Suzuki H, et al. α4β1and α6β1-integrins are functional receptors for midkine, a heparin-binding growth factor. J Cell Sci 2004; 117: 5405-15.
78. Stoica GE, Kuo A, Powers C, et al. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem 2002; 277: 35990-8.
79. Kuo AH, Stoica GE, Riegel AT, Wellstein A. Recruitment of insulin receptor substrate-1 and activation of NF-κB essential for midkine growth signaling through anaplastic lymphoma kinase. Oncogene 2007; 26: 859-69.
80. Huang Y, Hoque MO, Wu F, Trink B, Sidransky D, Ratovitski EA. Midkine induces epithelial-mesenchymal transition through Notch2/Jak2-Stat3 signaling in human keratinocytes. Cell Cycle 2008; 7: 1613-22.
81. Polykratis A, Katsoris P, Courty J, Papadimitriou E. Characterization of heparin affin regulatory peptide signaling in human endothelial cells. J Biol Chem 2005; 280: 22454-61.
82. Meng K, Rodriguez-Pena A, Dimitrov T, et al. Pleiotrophin signals increased tyrosine phosphorylation of β-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase β/ζ. Proc Natl Acad Sci U S A 2000; 97: 2603-8.
83. Ohuchida T, Okamoto K, Akahane K, et al. Midkine protects hepatocellular carcinoma cells against TRAIL-mediated apoptosis through down-regulation of caspase-3 activity. Cancer 2004;100: 2430-6.
84. Qi M, Ikematsu S, Ichihara-Tanaka K, Sakuma S, Muramatsu T, Kadomatsu K. Midkine rescues Wilms' tumor cells from cisplatininduced apoptosis: regulation of Bcl-2 expression by midkine. J Biochem 2000; 127: 269-77.
85. Huang Y, Sook-Kim M, Ratovitski E. Midkine promotes tetraspanin-integrin interaction and induces FAK-Stat1α pathway contributing to migration/invasiveness of human head and neck squamous cell carcinoma cells. Biochem Biophys Res Commun 2008; 377:474-8.
86. Cernkovich ER, Deng J, Hua K, Harp JB. Midkine is an autocrine activator of signal transducer and activator of transcription 3 in 3T3-L1 cells. Endocrinology 2007; 148: 1598-604.
87. Wang J, Takeuchi H, Sonobe Y, et al. Inhibition of midkine alleviates experimental autoimmune encephalomyelitis through the expansion of regulatory T cell population. Proc Natl Acad Sci U S A 2008; 105: 3915-20.
88. Take M, Tsutsui J, Obama H, et al. Identification of nucleolin as a binding protein for midkine (MK) and heparin-binding growth associated molecule (HB-GAM). J Biochem 1994; 116: 1063-8.
89. Shibata Y, Muramatsu T, Hirai M, et al. Nuclear targeting by the growth factor midkine. Mol Cell Biol 2002; 22: 6788-96.
90. Salama RH, Muramatsu H, Zou K, Inui T, Kimura T, Muramatsu T. Midkine binds to 37-kDa laminin binding protein precursor, leading to nuclear transport of the complex. Exp Cell Res 200; 270: 13-20.
91. Dai LC, Shao JZ, Min LS, Xiao YT, Xiang LX, Ma ZH. Midkine accumulated in nucleolus of HepG2 cells involved in rRNA transcription. World J Gastroenterol 2008; 14: 6249-53.
92. Mitsiadis TA, Muramatsu T, Muramatsu H, Thesleff I. Midkine (MK), a heparin-binding growth/differentiation factor, is regulated by retinoic acid and epithelial-mesenchymal interactions in the de-veloping mouse tooth, and affects cell proliferation and morpho-genesis. J Cell Biol 1995; 129: 267-81.
93. Toriyama K, Muramatsu H, Hoshino T, Torii S, Muramatsu T. Evaluation of heparin-binding growth factors in rescuing morpho-genesis of heparitinase-treated mouse embryonic lung explants. Differentiation 1997; 61: 161-7.
94. Ohta S, Muramatsu H, Senda T, Zou K, Iwata H, Muramatsu T. Midkine is expressed during repair of bone fracture and promotes chondrogenesis. J Bone Miner Res 1999; 14: 1132-44.
95. Neunaber C, Catala-Lehnen P Beil FT, et al. Increased trabecular bone formation in mice lacking the growth factor midkine. J Bone Miner Res 2010; 25: 1724-35.
96. Nakamura E, Kadomatsu K, Yuasa S, et al. Disruption of the mid-kine gene (Mdk) resulted in altered expression of a calcium binding protein in the hippocampus of infant mice and their abnormal be-haviour. Genes Cells; 3: 811-22.
97. Amet LE, Lauri SE, Hienola A, et al. Enhanced hippocampal long-term potentiation in mice lacking heparin-binding growth-associated molecule. Mol Cell Neurosci 2001; 17: 1014-24.
98. Muramatsu H, Zou P, Kurosawa N, et al. Female infertility in mice deficient in midkine and pleiotrophin, which form a distinct family of growth factors. Genes Cells 2006; 11: 1405-17.
99. Ikeda S, Ichihara-Tanaka K, Azuma T, Muramatsu T, Yamada M. Effects of midkine during in vitro maturation of bovine oocytes on subsequent developmental competence. Biol Reprod 2000; 63: 1067-74.
100. Ikeda S, Saeki K, Imai H, Yamada M. Abilities of cumulus and granulosa cells to enhance the developmental competence of bo-vine oocytes during in vitro maturation period are promoted by midkine; a possible implication of its apoptosis suppressing effects. Reproduction 2006; 132: 549-57.
101. Yokota C, Takahashi S, Eisaki A, et al. Midkine counteracts the activin signal in mesoderm induction and promotes neural forma-tion. J Biochem 1998; 123: 339-46.
102. Schafer M, Rembold M, Wittbrodt J, Schartl M, Winkler C. Medial floor plate formation in zebrafish consists of two phases and re-quires trunk-derived Midkine-a. Genes Dev 2005; 19: 897-902.
103. Liedtke D, Winkler C. Midkine-b regulates cell specification at the neural plate border in zebrafish. Dev Dyn 2008; 237: 62-74.
104. Griffith M. Midkine and secondary neurulation. Teratology 1997; 55: 213-23.
105. Zou P, Muramatsu H, Sone M, Hayashi H, Nakashima T, Mu-ramatsu T. Mice doubly deficient in the midkine and pleiotrophin genes exhibit deficits in the expression of -tectorin gene and in auditory response. Lab Invest. 2006; 86: 645-53.
106. Sone M, Muramatsu H, Muramatsu T, Nakashima T. Morphologi-cal observation of the stria vascularis in midkine and pleiotrophin knockout mice. Auris Nasus Larynx 2011; 38: 41-5.
107. Matsumoto K, Wanaka A, Takatsuji K, Muramatsu H, Muramatsu T, Tohyama M. A novel family of heparin-binding growth factors, pleiotrophin and midkine, is expressed in the developing rat cere-bral cortex. Brain Res Dev Brain Res 1994; 79: 229-41.
108. Sun XZ, Inouye M, Fukui Y, et al. An immunohistochemical study of radial glial cells in the mouse brain prenatally exposed to -irradiation. J Neuropathol Exp Neurol 199; 56: 1339-48.
109. Zou P, Muramatsu H, Miyata T, Muramatsu T. Midkine, a heparin-binding growth factor, is expressed in neural precursor cells and promotes their growth. J Neurochem 2006; 99: 1470-9.
110. Matsumoto K, Wanaka A, Mori T, et al. Localization of pleiotro-phin and midkine in the postnatal developing cerebellum. Neurosci Lett 1994; 178: 216-20.
111. Horiba M, Kadomatsu K, Yasui K, et al. Midkine plays a protec-tive role against cardiac ischemia/reperfusion injury through a re-duction of apoptotic reaction. Circulation 2006; 114: 1713-20.
112. Takenaka H, Horiba M, Ishiguro H, et al. Midkine prevents ven-tricular remodeling and improves long-term survival after myocardial infarction. Am J Physiol Heart Circ Physiol 2009; 296: H462-9.
113. Yoshida Y, Ikematsu S, Moritoyo T, et al. Intraventricular admini-stration of the neurotrophic factor midkine ameliorates hippocam-pal delayed neuronal death following transient forebrain ischemia in gerbils. Brain Res 2001; 894: 46-55.
114. Unoki K, Ohba N, Arimura H, Muramatsu H, Muramatsu T. Res-cue of photoreceptors from the damaging effects of constant light by midkine, a retinoic acid-responsive gene product. Invest Oph-thalmol Vis Sci 1994; 35: 4063-8.
115. Svensson SL, Pasupuleti M, Walse B, et al. Midkine and pleiotro-phin have bactericidal properties: preserved antibacterial activity in a family of heparin-binding growth factors during evolution. J Biol Chem 2010; 285: 16105-15.
116. Ruan M, Ji T, Wu Z, Zhou J, Zhang C. Evaluation of expression of midkine in oral squamous cell carcinoma and its correlation with tumour angiogenesis. Int J Oral Maxillofac Surg 2007; 36:159-64.
117. Aridome K, Tsutsui J, Takao S, et al. Increased midkine gene ex-pression in human gastrointestinal cancers. Jpn J Cancer Res 1995; 86: 655-61.
118. Maeda S, Shinchi H, Kurahara H, et al. Clinical significance of midkine expression in pancreatic head carcinoma. Br J Cancer 2007; 97: 405-11.
119. Garver RI, Jr., Chan CS, Milner PG. Reciprocal expression of pleiotrophin and midkine in normal versus malignant lung tissues. Am J Respir Cell Mol Biol.1993; 9: 463-6.
120. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. The angi-ogenic factor midkine is expressed in bladder cancer, and overex-pression correlates with a poor outcome in patients with invasive cancers. Cancer Res 1996; 56: 2515-8.
121. Konishi N, Nakamura M, Nakaoka S, et al. Immunohistochemical analysis of midkine expression in human prostate carcinoma. On-cology 1999; 57: 253-7.
122. Garver RI, Jr., Radford DM, Donis-Keller H, Wick MR, Milner PG. Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer 1994; 74: 1584-90.
123. Moon HS, Park WI, Sung SH, Choi EA, Chung HW, Woo BH. Immunohistochemical and quantitative competitive PCR analyses of midkine and pleiotrophin expression in cervical cancer. Gynecol Oncol 2003; 88: 289-97.
124. Tanabe K, Matsumoto M, Ikematsu S, et al. Midkine and its clini-cal significance in endometrial carcinoma. Cancer Sci 2008; 99: 1125-30.
125. Nakanishi T, Kadomatsu K, Okamoto T, Tomoda Y, Muramatsu T. Expression of midkine and pleiotrophin in ovarian tumors. Obstet Gynecol 1997 Aug;90(2):285-90.
126. Maehara H, Kaname T, Yanagi K, et al. Midkine as a novel target for antibody therapy in osteosarcoma. Biochem Biophys Res Commun 2007; 358: 757-62.
127. Jin Z, Lahat G, Korchin B, et al. Midkine enhances soft-tissue sarcoma growth: a possible novel therapeutic target. Clin Cancer Res 2008; 14: 5033-42.
128. Nakagawara A, Milbrandt J, Muramatsu T, et al. Differential ex-pression of pleiotrophin and midkine in advanced neuroblastomas. Cancer Res 1995; 55: 1792-7.
129. Mishima K, Asai A, Kadomatsu K, et al. Increased expression of midkine during the progression of human astrocytomas. Neurosci Lett 1997; 233: 29-32.
130. Tong Y, Mentlein R, Buhl R, et al. Overexpression of midkine contributes to anti-apoptotic effects in human meningiomas. J Neurochem 2007; 100: 1097-107.
131. Hidaka H, Yagasaki H, Takahashi Y, et al. Increased midkine gene expression in childhood B-precursor acute lymphoblastic leukemia. Leuk Res 2007; 31: 1045-51.
132. Ye C, Qi M, Fan QW, et al. Expression of midkine in the early stage of carcinogenesis in human colorectal cancer. Br J Cancer 1999; 79: 179-84.
133. Sakitani H, Tsutsumi M, Kadomatsu K, et al. Overexpression of midkine in lung tumors induced by N-nitrosobis(2hydroxypropyl)amine in rats and its increase with progression. Carcinogenesis 1999; 20: 465-9.
134. Mashour GA, Ratner N, Khan GA, Wang HL, Martuza RL, Kurtz A. The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells. Oncogene. 2001; 20: 97-105.
135. Kadomatsu K, Hagihara M, Akhter S, Fan QW, Muramatsu H, Muramatsu T. Midkine induces the transformation of NIH3T3 cells. Br J Cancer 1997; 75: 354-9.
136. Kang HC, Kim IJ, Park JH, et al. Identification of genes with dif-ferential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res 2004; 10: 272-84.
137. Mirkin BL, Clark S, Zheng X, et al. Identification of midkine as a mediator for intercellular transfer of drug resistance. Oncogene 2005; 24: 4965-74.
138. Mashima T, Sato S, Sugimoto Y, Tsuruo T, Seimiya H. Promotion of glioma cell survival by acyl-CoA synthetase 5 under extracellu-lar acidosis conditions. Oncogene 2009; 28: 9-19.
139. Choudhuri R, Zhang HT, Donnini S, Ziche M, Bicknell R. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res 1997; 57: 1814-9.
140. Muramatsu H, Song XJ, Koide N, et al. Enzyme-linked immunoas-say for midkine, and its application to evaluation of midkine levels in developing mouse brain and sera from patients with hepatocellu-lar carcinomas. J Biochem 1996; 119: 1171-5.
141. Ikematsu S, Yano A, Aridome K, et al. Serum midkine levels are increased in patients with various types of carcinomas. Br J Cancer 2000; 83: 701-6.
142. Muramatsu T, Muramatsu H. Glycosaminoglycan-binding cytoki-nes as tumor markers. Proteomics 2008; 8: 3350-9.
143. Salama RH, Muramatsu H, Kobayashi H, Nomura S, Mizutani S, Muramatsu T. Serum levels of midkine, a heparin-binding growth factor, increase in both malignant and gynecological tumors. Re-prod Immunol Biol 2006; 21: 64-70.
144. Song XJ, Muramatsu H, Aridome K, et al. The Serum level of midkine, a heparin-binding growth factor, as a tumor marker. Biomed Res 1997; 18: 375-81.
145. Shimada H, Nabeya Y, Tagawa M, et al. Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci 2003; 94: 628-32.
146. Jia HL, Ye QH, Qin LX, et al. Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Can-cer Res 2007; 13: 1133-9.
147. Ikematsu S, Nakagawara A, Nakamura Y, et al. Correlation of elevated level of blood midkine with poor prognostic factors of human neuroblastomas. Br J Cancer.2003; 88: 1522-6.
148. Ikematsu S, Nakagawara A, Nakamura Y, et al. Plasma midkine level is a prognostic factor for human neuroblastoma. Cancer Sci 2008; 99: 2070-4.
149. Ibusuki M, Fujimori H, Yamamoto Y, et al. Midkine in plasma as a novel breast cancer marker. Cancer Sci. 2009; 100: 1735-9.
150. Ikematsu S, Okamoto K, Yoshida Y, et al. High levels of urinary midkine in various cancer patients. Biochem Biophys Res Commun 2003; 306: 329-32.
151. Maruyama K, Muramatsu H, Ishiguro N, Muramatsu T. Midkine, a heparin-binding growth factor, is fundamentally involved in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 2004; 50: 1420-9.
152. Salama RH, Muramatsu H, Shimizu E, et al. Increased midkine levels in sera from patients with Alzheimer's disease. Prog Neuro-psychopharmacol Biol Psychiatry 2005; 29: 611-6.
153. Kitahara T, Shishido T, Suzuki S, et al. Serum midkine as a predic-tor of cardiac events in patients with chronic heart failure. J Card Fail 2010; 16: 308-13.
154. Miyashiro I, Kaname T, Shin E, et al. Midkine expression in hu-man breast cancers: expression of truncated form. Breast Cancer Res Treat 1997; 43: 1-6.
155. Aridome K, Takao S, Kaname T, et al. Truncated midkine as a marker of diagnosis and detection of nodal metastases in gastroin-testinal carcinomas. Br J Cancer 1998; 78: 472-7.
156. Paul S, Mitsumoto T, Asano Y, Kato S, Kato M, Shinozawa T. Detection of truncated midkine in Wilms' tumor by a monoclonal antibody against human recombinant truncated midkine. Cancer Lett 2001; 163: 245-51.
157. Nobata S, Shinozawa T, Sakanishi A. Truncated midkine induces transformation of cultured cells and short latency of tumorigenesis in nude mice. Cancer Lett 2005; 219: 83-9.
158. Ezquerra L, Herradon G, Nguyen T, Silos-Santiago I, Deuel TF. Midkine, a newly discovered regulator of the renin-angiotensin pathway in mouse aorta: significance of the pleiotrophin/midkine developmental gene family in angiotensin II signaling. Biochem Biophys Res Commun 2005; 333: 636-43.
159. Helleboid-Chapman A, Nowak M, Helleboid S, et al. Apolipopro-tein A-V modulates insulin secretion in pancreatic -cells through its interaction with midkine. Cell Physiol Biochem 2009; 24: 451-60.
160. Wang S, Yoshida Y, Goto M, et al. Midkine exists in astrocytes in the early stage of cerebral infarction. Brain Res Dev Brain Res 1998; 106: 205-9.
161. Mochizuki R, Takeda A, Sato N, et al. Induction of midkine ex-pression in reactive astrocytes following rat transient forebrain ischemia. Exp Neurol 1998; 149: 73-8.
162. Takada J, Ooboshi H, Ago T, et al. Postischemic gene transfer of midkine, a neurotrophic factor, protects against focal brain ische-mia. Gene Ther 2005; 12: 487-93.
163. Ishikawa E, Ooboshi H, Kumai Y, et al. Midkine gene transfer protects against focal brain ischemia and augments neurogenesis. J Neurol Sci 2009; 285: 78-84.
164. Kim YB, Ryu JK, Lee HJ, et al. Midkine, heparin-binding growth factor, blocks kainic acid-induced seizure and neuronal cell death in mouse hippocampus. BMC Neurosci 2010; 11: 42.
165. Kohno S, Nakagawa K, Hamada K, et al. Midkine promoter-based conditionally replicative adenovirus for malignant glioma therapy. Oncol Rep. 2004;12: 73-8.
166. Yu L, Hamada K, Namba M, et al. Midkine promoter-driven sui-cide gene expression and -mediated adenovirus replication pro-duced cytotoxic effects to immortalised and tumour cells. Eur J Cancer 2004; 40: 1787-94.
167. Toyoda E, Doi R, Kami K, et al. Midkine promoter-based condi-tionally replicative adenovirus therapy for midkine-expressing hu-man pancreatic cancer. J Exp Clin Cancer Res 2008; 27: 30.
168. Terao S, Shirakawa T, Kubo S, et al. Midkine promoter-based conditionally replicative adenovirus for targeting midkine-expressing human bladder cancer model. Urology; 70: 1009-13.
169. Adachi Y, Reynolds PN, Yamamoto M, et al. A midkine promoter-based conditionally replicative adenovirus for treatment of pediat-ric solid tumors and bone marrow tumor purging. Cancer Res 2001;61: 7882-8.
170. Tomizawa M, Yu L, Wada A, et al. A promoter region of the midkine gene that is frequently expressed in human hepatocellular car-cinoma can activate a suicide gene as effectively as the-fetoprotein promoter. Br J Cancer 2003; 89: 1086-90.
171. Adachi Y, Reynolds PN, Yamamoto M, et al. Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors. Cancer Res 2000; 60: 4305-10.
172. Takei Y, Kadomatsu K, Goto T, Muramatsu T. Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts. Cancer 2006; 107: 864-73.
173. Salama RH, Muramatsu H, Zou P, Okayama M, Muramatsu T. Midkine, a heparin-binding growth factor, produced by the host enhances metastasis of Lewis lung carcinoma cells. Cancer Lett. 2006; 233: 16-20.
174. Dai LC, Yao X, Wang X, et al. In vitro and in vivo suppression of hepatocellular carcinoma growth by midkine-antisense oligonu-cleotide-loaded nanoparticles. World J Gastroenterol 2009; 15: 1966-72.
175. Grzelinski M, Steinberg F, Martens T, Czubayko F, Lamszus K, Aigner A. Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK. Neoplasia 2009; 11: 145-56
176. Yasuhara O, Muramatsu H, Kim SU, Muramatsu T, Maruta H, McGeer PL. Midkine, a novel neurotrophic factor, is present in se-nile plaques of Alzheimer disease. Biochem Biophys Res Commun 1993; 192: 246-51.
177. Yu GS, Hu J, Nakagawa H. Inhibition of -amyloid cytotoxicity by midkine. Neurosci Lett 1998; 254:125-8.
178. Monji A, Yoshida I, Tashiro K, Hayashi Y, Matsuda K, Tashiro N. Inhibition of A beta fibril formation and A beta-induced cytotoxic-ity by senile plaque-associated proteins. Neurosci Lett 2000; 278: 81-4.
179. Muramatsu H, Yokoi K, Chen L, Ichihara-Tanaka K, Kimura T, Muramatsu T. Midkine as a factor to counteract the deposition of amyloid-peptide plaques: in vitro analysis and examination in knockout mice. Int Arch Med 2011; 4, 1.
180. Yasuhara O, Schwab C, Matsuo A, et al. Midkine-like immunore-activity in extracellular neurofibrillary tangles in brains of patients with parkinsonism-dementia complex of Guam. Neurosci Lett 1996; 205: 107-10.
181. Kato S, Shinozawa T, Takikawa M, et al. Midkine, a new neurotrophic factor, is present in glial cytoplasmic inclusions of multi-ple system atrophy brains. Acta Neuropathol 2000; 100: 481-9.
182. Flatscher-Bader T, Wilce PA. Impact of alcohol abuse on protein expression of midkine and excitatory amino acid transporter 1 in the human prefrontal cortex. Alcohol Clin Exp Res 2008; 32: 184958.
183. Ezquerra L, Perez-Garcia C, Garrido E, et al. Morphine and yohimbine regulate midkine gene expression in the rat hippocampus. Eur J Pharmacol 2007; 557: 147-50.
184. Ohgake S, Shimizu E, Hashimoto K, et al. Dopaminergic hypo-functions and prepulse inhibition deficits in mice lacking midkine. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 541-6.
185. Yao X, Tan Z, Gu B, et al. Promotion of self-renewal of embryonic stem cells by midkine. Acta Pharmacol Sin 2010; 31: 629-37.
186. Murasugi A, Tohma-Aiba Y. Production of native recombinant human midkine in the yeast, Pichia pastoris. Protein Expr Purif 2003; 27: 244-52.
187. Inui T, Bodi J, Kubo S, et al. Solution synthesis of human midkine, a novel heparin-binding neurotrophic factor consisting of 121 amino acid residues with five disulphide bonds. J Pept Sci 1996; 2: 28-39.
188. Matsuda Y, Talukder AH, Ishihara M, et al. Limited proteolysis by chymotrypsin of midkine and inhibition by heparin binding. Bio-chem Biophys Res Commun 1996; 228: 176-81.
189. Sato W, Takei Y, Yuzawa Y, Matsuo S, Kadomatsu K, Muramatsu T. Midkine antisense oligodeoxyribonucleotide inhibits renal dam-age induced by ischemic reperfusion. Kidney Int 2005; 67: 1330-9.
190. Banno H, Takei Y, Muramatsu T, Komori K, Kadomatsu K. Con-trolled release of small interfering RNA targeting midkine attenu-ates intimal hyperplasia in vein grafts. J Vasc Surg 2006; 44: 633-41.
191. Hayashi K, Banno H, Kadomatsu K, Takei Y, Komori K, Mu-ramatsu T. Antisense oligodeoxyribonucleotide as to the growth factor midkine suppresses neointima formation induced by balloon injury. Am J Physiol Heart Circ Physiol 2005; 288: H2203-9.
192. Yamamoto H, Muramatsu H, Nakanishi T, et al. Midkine as a molecular target: comparison of effects of chondroitin sulfate E and siRNA. Biochem Biophys Res Commun 2006; 351: 915-9.
193. Matsui T, Ichihara-Tanaka K, Lan C, et al. Midkine inhibitors: application of a simple assay procedure to screening of inhibitory compounds. Int Arch Med 2010; 3: 12.
194. Winkler C, Moon RT. Zebrafish mdk2, a novel secreted midkine, participates in posterior neurogenesis. Dev Biol 2001; 229: 102-18.
195. Chen S, Bu G, Takei Y, et al. Midkine and LDL-receptor-related protein 1 contribute to the anchorage-independent cell growth of cancer cells. J Cell Sci 2007; 120: 4009-15.
196. Sumi Y, Muramatsu H, Hata K, Ueda M, Muramatsu T. Midkine enhances early stages of collagen gel contraction. J Biochem 2000; 127: 247-51.
197. Inazumi T, Tajima S, Nishikawa T, Kadomatsu K, Muramatsu H, Muramatsu T. Expression of the retinoid-inducible polypeptide, midkine, in human epidermal keratinocytes. Arch Dermatol Res 1997; 289: 471-5.
198. Zhou H, Muramatsu T, Halfter W, Tsim KW, Peng HB. A role of midkine in the development of the neuromuscular junction. Mol Cell Neurosci 1997; 10: 56-70.
199. Sakakima H, Yoshida Y, Yamazaki Y, et al. Disruption of the midkine gene (Mdk) delays degeneration and regeneration in in-jured peripheral nerve. J Neurosci Res 2009; 87: 2908-15.
200. Ochiai K, Muramatsu H, Yamamoto S, Ando H, Muramatsu T. The role of midkine and pleiotrophin in liver regeneration. Liver Int 2004; 24: 484-91.
201. Kawai H, Sato W, Yuzawa Y, et al. Lack of the growth factor midkine enhances survival against cisplatin-induced renal damage. Am J Pathol 2004; 165: 1603-12.
202. Kosugi T, Yuzawa Y, Sato W, et al. Growth factor midkine is involved in the pathogenesis of diabetic nephropathy. Am J Pathol 2006; 168: 9-19.
203. Inoh K, Muramatsu H, Ochiai K, Torii S, Muramatsu T. Midkine, a heparin-binding cytokine, plays key roles in intraperitoneal adhe-sions. Biochem Biophys Res Commun 2004; 317: 108-13.